How the Global Fund to Fight AIDS, Tuberculosis and Malaria is being implemented in four African countries

The London School of Hygiene & Tropical Medicine will today publish interim findings relating to how the Global Fund to Fight AIDS, Tuberculosis and Malaria is being implemented in four African countries.

The Fund was established in 2002 as a mechanism to get additional resources to affected countries to control these devastating diseases.

The findings, which appear in the Lancet, are based on interviews with 137 national level respondents. They reveal that the conditions set by the Global Fund around performance-based payments will be difficult for fund recipients and sub-recipients to meet, and that the Fund’s goals may be threatened as a result. They also indicate that delays in getting funds to those who will use them have frustrated hopes of a quick scaling-up of disease control interventions.

The paper’s lead author, Ruairí Brugha, Senior Lecturer in Public Health at LSHTM, comments: ‘The Global Fund is one of several new global initiatives to finance HIV/AIDS control, each superimposed on the systems which already exist in the countries being targeted. What our interim findings show is that the Global Fund’s goals will only be met if there are clearer guidelines, significant improvements in co-ordination among donors, and with simpler and more straightforward funding, planning, management and reporting systems’.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Quabodepistat combo shows promise for safer, faster tuberculosis treatment